TY  - JOUR
AU  - Santo, L
AU  - Teras, LR
AU  - Giles, GG
AU  - Weinstein, SJ
AU  - Albanes, D
AU  - Wang, Y
AU  - Pfeiffer, RM
AU  - Lan, Q
AU  - Rothman, N
AU  - Birmann, BM
AU  - Colditz, GA
AU  - Pollak, MN
AU  - Purdue, MP
AU  - Hofmann, JN
Y2  - 2020/12/21
Y1  - 2017/10/10
SN  - 0007-0920
UR  - http://hdl.handle.net/11343/257404
AB  - BACKGROUND: Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively. METHODS: We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium. RESULTS: In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; Ptrend=0.03). No association was observed for women. CONCLUSIONS: This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.
LA  - English
PB  - NATURE PUBLISHING GROUP
T1  - Circulating resistin levels and risk of multiple myeloma in three prospective cohorts
DO  - 10.1038/bjc.2017.282
IS  - British Journal of Cancer
VL  - 117
IS  - 8
SP  - 1241-1245
L1  - /bitstream/handle/11343/257404/PMC5674102.pdf?sequence=1&isAllowed=y
ER  -